Opportunities for diagnosing cytomegalovirus in pulmonary infections Cytomegalovirus (CMV) infection is considered a major cause ofmorbidity and mortality in organ and bone marrow transplant recipients and patients with the acquired immune deficiency syndrome (AIDS). Untreated CMV pneumonia carries a mortality approaching 100%. Other syndromes may include fever with or without lymphocytosis, retinitis, encephalitis, duodenitis, and colitis, although only the first satisfies strict criteria for a causal association with the virus. ' Two hypotheses have been proposed to explain the pathogenesis of CMV pneumonia. Either pre-existing lung damage and immunodeficiency reduce the magnitude of virus-induced tissue destruction required to produce pneumonia,2 or the pneumonia reflects T cell-mediated immune reactivity directed against CMV antigens.3 The first predicts a preventative role for avoidance of iatrogenic immunosuppression or pulmonary toxins, whereas the second is compatible with a therapeutic role for CMV immunoglobulin. The severity of CMV pneumonia in thoracic allograft recipients which led to the study reported by Egan and colleagues on pages 9-13 of this issue of Thorax4 is explained either by immunosuppression and pre-existing lung damage2 or by T cell immunopathology associated with lung rejection. 3 Many strategies may limit the clinical impact of CMV pneumonia. Anti-CMV chemotherapy with ganciclovir or foscamet are often ineffective in established CMV pneumonia.5 Adjunctive CMV immunoglobulin therapy was suggested to block T cell immunoreactivity against CMV antigens, but the pathogenic role of such immunopathology2 and the efficacy of immunotherapy remain unproven. 6 Prophylactic high dose acyclovir is safe and possibly effective.7 Pre-emptive ganciclovir treatment when pulmonary CMV infection is detected by bronchoalveolar lavage has been shown to be efficacious.8 Nonetheless, the potential benefit of prophylactic ganciclovir for all immunosuppressed patients must be balanced against the possible emergence of pathogenic drug-resistant virus.9 Both ganciclovir and foscamet have major adverse effects -bone marrow suppression and nephrotoxicity, respectively -and the synergistic myelotoxicity of ganciclovir and zidovudine largely preclude their combined administration.'1 Prophylactic CMV immunoglobulin may have a role in high risk CMV seronegative organ transplant recipients whose donors are seropositive."' Preferential matching of organ transplant recipients and donors for either CMV antibody status or HLA antigens has been proposed, the former to avoid the high risk CMV positive donor, CMV negative recipient combination,'2 and the latter to minimise graft rejection and hence severe CMV disease associated with immunosuppressive antirejection treatment."' Graft survival is improved by HLA matching in renal and cardiac transplant recipients,'415 and graft rejection could be reduced by DR antigen matching in heart transplant recipients. 6 Increased graft rejection consequent on CMV matching at the expense of HLA mismatching could therefore lead to increased iatrogenic immunosuppression. The rapid latex agglutination assay used to determine donor and recipient CMV antibody status immediately before transplantation is prone to produce occasional false negative'7 and false positive results. ' HIA matching appears to be associated with a low incidence of graft loss and severe CMV disease in renal allograft recipients, presumably because iatrogenic immunosuppression is thereby minimised.'3'419 At present, heart, heart-lung, and lung allograft recipients and their donors are largely matched for CMV antibody status rather than HLA antigens.12 Prospective HLA matching in thoracic transplantation should improve its success'6 and also minimise severe CMV disease. '3 Progress in the rapid diagnosis of CMV disease followed the development of An alternative approach to the early identification of patients who will subsequently develop CMV disease is the assay of CMV viraemia. Blood anticoagulated with preservative-free heparin is inoculated on human fibroblast cell monolayers, and immediate early antigen detection is performed 24- 
